预约演示
更新于：2025-09-10
Fibrin Sealant (Baxter)
更新于：2025-09-10
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2000-02-07), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
关联
36
项与 Fibrin Sealant (Baxter) 相关的临床试验TCTR20240924011
Phase II/III to evaluate the safety and efficacy of Thai Red Cross Society fibrin sealant compared with commercially available fibrin sealant (TISSEEL) in post-operative air leak. A randomized controlled trial
开始日期2024-11-01 |
TCTR20240723010
Phase II/III open-label randomized-controlled trial to evaluate the safety and efficacy of Fibrin sealant Thai Red Cross Society compared with commercially available fibrin sealant (TISSEEL) in pterygium volunteer
开始日期2024-10-09 |
CTRI/2023/06/053870
Randomised controlled trial comparing the efficacy of autologous platelet rich fibrin therapy versus hydrocolloid gel dressing in chronic non-healing cutaneous ulcers, an open label study from Eastern India.
开始日期2023-06-30 |
申办/合作机构- |
100 项与 Fibrin Sealant (Baxter) 相关的临床结果
登录后查看更多信息
100 项与 Fibrin Sealant (Baxter) 相关的转化医学
登录后查看更多信息
100 项与 Fibrin Sealant (Baxter) 相关的专利（医药）
登录后查看更多信息
361
项与 Fibrin Sealant (Baxter) 相关的文献（医药）2025-08-01·Acta Biomaterialia
Chlorocatechol-functionalized gelatin nanoparticles as a hemostatic agent with antimicrobial properties
Article
作者: Wang, Kan ; Razaviamri, Fatemeh ; Zhang, Zhongtian ; Lee, Bruce P ; Manuel, James
Hemorrhage is one of the leading preventable causes of death associated with trauma, which is often complicated by wound infection. Current hemostatic materials are not ideal and lack antimicrobial properties needed for infection prevention. Here, we tested the feasibility for 6-chlorodopamine-functionalized gelatin (GDC) nanoparticles to function as a hemostatic powder with strong tissue adhesion and antibacterial properties. 6-Chlorodopamine contains a catechol sidechain that is further modified with an electron withdrawing chlorine atom, and provides strong tissue adhesion and antimicrobial property. These gelatin nanoparticles are not covalently crosslinked, which enablde them to rapidly transition into an adhesive film when hydrated with an aqueous solution or blood. The chlorination of catechol significantly increased structural integrity, interfacial bonding to tissue surface, and the rate of film formation. Additionally, GDC nanoparticles are noncytotoxic and nonhemolytic, and effectively killed Gram-positive (Staphylococcus epidermidis, Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria. Finally, GDC nanoparticles achieved significantly faster hemostasis and reduced blood loss when compared to a commercial fibrin glue, Tisseel, in tail transection and liver hemorrhage models performed in mice. These findings highlight the potential of GDC nanoparticle as a versatile, multifunctional hemostatic agent capable of both rapid hemorrhage control and infection prevention. STATEMENT OF SIGNIFICANCE: Existing hemostatic agents often lack effective antimicrobial properties and may not be suited for application in a prehospital setting. This work evaluated a multifunctional, hemostatic nanoparticle that addresses key challenges in hemorrhage control and infection prevention, through a simple, bioinspired formulation. Gelatin nanoparticles were functionalized with chlorocatechol (GDC) that can rapidly transition into adhesive films when hydrated with blood. Chlorocatechol imparted the nanoparticles with strong tissue adhesion, film integrity, and antimicrobial property. In mouse hemorrhage models, GDC significantly reduced blood loss and bleeding time when compared to a commercial fibrin sealant. This powder-form material requires no mixing or specialized equipment to deploy, which makes it potentially suitable for application in a prehospital setting.
2025-07-01·Cureus Journal of Medical Science
Sequential Surgical Management of a Recurrent Complex Transsphincteric Anal Fistula With Sphincter Disruption: A Case Report.
Article
作者: Abarca-Magallón, Alfredo Sinahi ; Pérez-Valdez, Diego ; Valdivieso-Siguenza, Daniel Alejandro ; Hernández-Alvarado, Samuel ; Castañeda-Rodríguez, Daniel
High transsphincteric anal fistulas represent a significant therapeutic challenge due to the risk of fecal incontinence associated with division of the sphincter complex. Management must be individualized, particularly in recurrent cases. We report the case of a 55-year-old male with a recurrent high posterior transsphincteric anal fistula who had undergone multiple previous surgical interventions. Initial treatment with fistulectomies and cryptectomies resulted in disruption of both the internal and external anal sphincters, leading to severe fecal incontinence. Due to persistent fistulous drainage, the patient underwent diagnostic laparoscopy with creation of a protective loop ileostomy, irrigation and drainage of the tract, primary transanal closure of the internal opening, and application of fibrin sealant (Tisseel®, Baxter Healthcare Corporation, Deerfield, IL). In the outpatient setting, tract curettage using a CitoBrush® (Medscand AB, Malmö, Sweden) and repeat application of fibrin sealant were performed. Subsequent examination under anesthesia revealed fibrosis without evidence of an active tract. Intestinal continuity was ultimately restored. The patient's postoperative course was favorable, with no recurrence or continence impairment. This case illustrates the importance of a stepwise surgical approach integrating conventional and adjunctive techniques for the treatment of complex anal fistulas. The combined use of sphincteroplasty, temporary fecal diversion, and biological sealants provided effective disease control while preserving sphincter function. Current evidence supports the use of fibrin sealants as adjuncts in fibrotic tracts and the role of temporary diversion in cases involving sphincter disruption. Sequential and patient-specific surgical management led to successful resolution of the fistula without compromising continence. This multidisciplinary strategy may be considered in patients with complex anatomy and a history of multiple surgical failures.
2025-06-25·Cureus Journal of Medical Science
Evaluating the Utility of Topical Haemostatic Adjuncts in Transoral Robotic Surgery (TORS)
Article
作者: Sattar, Zakariya ; Ahsan, Syed Farhan ; Watts, Emma
INTRODUCTION:
Transoral robotic surgery (TORS) is a minimally invasive modern surgical technique, offering novel access to the oral cavity with important implications for the management of oropharyngeal squamous cell carcinoma. However, TORS carries complications including haemorrhage, pain and impaired swallowing, with potentially significant implications for patients and healthcare systems.
AIM:
This combined retrospective cohort study and literature review aims to explore our experience with the use of topical haemostatic products in TORS to improve post-operative outcomes.
METHODS:
We analysed our experience with the use of three different topical haemostatic adjuncts during TORS procedures at a major head and neck cancer centre from October 2023 to August 2024. The primary outcome measure was the rate of post-operative haemorrhage. This cohort study was complemented by a systematic review of the existing literature regarding the use of topical haemostatic products in TORS.
RESULTS:
Eighteen patients met criteria for inclusion. The type of topical haemostatic adjunct used varied between Tisseel (n=8, 44.4%), Floseal (n=4, 22.2%) and Purabond (n=6, 33.3%). One patient (5.6%) developed a secondary post-operative haemorrhage. Another patient (n=1, 5.6%) required admission for management of post-operative pain. Our experience provides preliminary insight into the utility of topical haemostatic adjuncts in TORS and underlines the need for further research in this area.
CONCLUSION:
Topical haemostatic adjuncts, in our view, are useful, surgeon-friendly products that may augment haemostasis in TORS. Further studies are required to determine the efficacy of individual topical haemostatic products in preventing post-operative haemorrhage and enhancing recovery following TORS.
2
项与 Fibrin Sealant (Baxter) 相关的新闻（医药）2024-01-30
RION's Phase 2A clinical trial focuses on evaluating the safety and efficacy of Platelet Exosome Product™ (PEP™) combined with TISSEEL fibrin sealant for treating Diabetic Foot Ulcers (DFU).
Diabetic Foot Ulcers, affecting 18.6 million people worldwide each year, significantly impact quality of life and impose substantial economic burdens on healthcare systems.
The trial is a key part of RION's broader efforts in regenerative medicine, aiming to address unmet needs in the treatment of chronic conditions such as DFU.
ROCHESTER, Minn.--(BUSINESS WIRE)-- RION, a clinical-stage regenerative medicine company, at the forefront of the exosome therapeutic revolution, has officially commenced a Phase 2A study aimed at assessing the efficacy and safety of its exclusive exosome regenerative therapeutic, known as Purified Exosome Product™ (PEP™), for the management of Diabetic Foot Ulcers (DFU).
This press release features multimedia. View the full release here:
RION, located in Rochester, MN, is internationally recognized for its pioneering advancements in isolating and mass-producing platelet-derived exosomes. (Photo: Business Wire)
Diabetic Foot Ulcers affect approximately 18.6 million people worldwide each year1 and are associated with increasing rates of amputation and death. The economic burden of DFUs is substantial, imposing $13 billion in cost on the US public and private healthcare systems.2 The trial is a key part of RION's broader efforts in regenerative medicine, aiming to address unmet needs in the treatment of chronic conditions such as DFU.
Building on the success of the Phase 1B study conducted at Mayo Clinic, RION's Phase 2A trial represents a significant step forward in the development of a regenerative biologic for Diabetic Foot Ulcers. This prospective, randomized, multi-center study will involve 40 patients across the United States. Patients will be divided into two cohorts: one receiving standard care and the other treated with PEP™ exosomes, enabling a thorough comparison of outcomes.
A positive outcome in the Phase 2A trial has the potential to pave the way for a pivotal study followed by the submission of a Biologics License Application (BLA). PEP™ addresses a significant unmet medical need in the realm of diabetic wound care.
Dr. Atta Behfar, Co-founder of RION, said, “The progress we've made in advancing PEP™, reflects our deep commitment to developing powerful exosome therapies that unleash the body’s ability to heal from within. Not only will this study address a critical unmet need in chronic wound care, but it’s a pivotal moment for RION. We are disrupting the boundaries of exosome technology, to develop a new generation of therapies endowed with the potential to truly transform the way we treat complex and incurable diseases.”
In the United States, the treatment of DFUs remains a significant challenge in the medical community, with no new biologics approved by the US FDA for diabetic wounds since the late 1990s3. RION is committed to bringing exosome-based therapies to patients as quickly and safely as possible to transform the management and outcomes of this devastating condition.
About RION
RION was born out of the Mayo Clinic after two decades of research and innovation at that institution. RION is located in Rochester, MN and is internationally recognized for its pioneering advancements in isolating and mass-producing platelet-derived regenerative exosomes into shelf stable PEP™.
RION is rewriting the regenerative medicine playbook. Our cutting-edge proprietary biomanufacturing platform crafts the future of regenerative therapy, unlocking the potent secrets within these tiny cellular messengers. RION’s regenerative PEP™ technology will be integral to the therapeutic exosome revolution.
About PEP™
RION's Purified Exosome Product™ (PEP™) is a shelf stable product in a lyophilized powder derived from human platelets that contains stabilized platelet-derived regenerative exosomes. PEP™ is an exosome therapeutic that is designed to promote cell growth and formation of new blood vessels, while also reducing inflammation and protecting cells. RION and its scientific collaborators have performed extensive research showing the potential of PEP™ to heal a wide array of damaged tissue. The company is currently evaluating PEP™ in preclinical and clinical studies for several indications. While our focus remains on wound healing, multiple IND-enabling efforts in musculoskeletal, cardiovascular disease, pulmonary disease and women’s health disorders are creating new solutions where current standards of care cannot address unmet clinical needs.
About Diabetic Foot Ulcers (DFU)
Diabetic foot ulcers (DFUs) are not just wounds. These slow-healing sores on the feet are a brutal consequence of diabetes, inflicting a triple threat: excruciating pain, crippling mobility, and the specter of amputation. The numbers paint a grim picture. Up to 25% of people with diabetes will face a DFU in their lifetime4, and for almost a quarter of them also limb amputation5. In fact, every three and a half minutes in the US, a DFU becomes an amputation6. This isn't just a statistic, it's a story of lives shattered, livelihoods lost, and families forever changed. Many patients endure the agony of recurrences, their lives trapped in a cycle of healing and reopening wounds. And sadly, the shadow of mortality looms large. 40% of DFU sufferers will succumb to the condition7, making it a pervasive silent killer of diabetic communities. The economic cost is equally staggering. DFUs drain healthcare systems, piling on direct treatment expenses and crippling indirect costs from lost productivity and long-term disability.
RION's journey is paved with unwavering determination. We seek to break the cycle of pain, loss, and economic burden through application of our next-generation regenerative exosome technology. We will remain undeterred in our pursuit to have PEP™ become the first biologic to be approved for the treatment of DFU in over 25 years.
References
1.
Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic Foot Ulcers: A Review. JAMA. 2023 Jul 3;330(1):62-75. doi: 10.1001/jama.2023.10578. PMID: 37395769; PMCID: PMC10723802.
2.
Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care. 2014;37(3):651-8. doi: 10.2337/dc13-2176. Epub 2013 Nov 1. Erratum in: Diabetes Care. 2014 Sep;37(9):2660. PMID: 24186882.
3.
Fang RC, Galiano RD. A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Biologics. 2008 Mar;2(1):1-12. doi: 10.2147/btt.s1338. PMID: 19707423; PMCID: PMC2727777.
4.
Yazdanpanah L, Shahbazian H, Nazari I, Arti HR, Ahmadi F, Mohammadianinejad SE, Cheraghian B, Hesam S. Incidence and Risk Factors of Diabetic Foot Ulcer: A Population-Based Diabetic Foot Cohort (ADFC Study)-Two-Year Follow-Up Study. Int J Endocrinol. 2018 Mar 15;2018:7631659. doi: 10.1155/2018/7631659. PMID: 29736169; PMCID: PMC5875034.
5.
Liao X, Li SH, El Akkawi MM, Fu XB, Liu HW, Huang YS. Surgical amputation for patients with diabetic foot ulcers: A Chinese expert panel consensus treatment guide. Front Surg. 2022 Nov 8;9:1003339. doi: 10.3389/fsurg.2022.1003339. PMID: 36425891; PMCID: PMC9679004.
6.
Amputation Prevention Alliance. (n.d.). Amputation prevention alliance. Amputation Prevention Alliance | ADA.
7.
Jeyaraman K, Berhane T, Hamilton M, Chandra AP, Falhammar H. Mortality in patients with diabetic foot ulcer: a retrospective study of 513 cases from a single Centre in the Northern Territory of Australia. BMC Endocr Disord. 2019 Jan 3;19(1):1. doi: 10.1186/s12902-018-0327-2. PMID: 30606164; PMCID: PMC6318899.
临床2期上市批准
2022-06-11
NEW YORK, June 11, 2022 /PRNewswire/ -- As per the Zion Market Research study,
The global
tissue sealants and tissue adhesive market
was worth around USD 1.5 billion in 2021 and is estimated to grow to about USD 2.9 billion by 2028, with a compound annual growth rate (CAGR) of approximately 8.6 percent over the forecast period. The report analyzes the tissue sealants and tissue adhesive market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the tissue sealants and tissue adhesive market.
Key Industry Insights &Findings of the Tissue Sealants and Tissue Adhesive Market Reports:
As per the analysis shared by our research analyst, the Tissue Sealants and Tissue Adhesive Market is expected to grow annually at a CAGR of around
8.6% (2022-2028).
Through the primary research, it was established that the Cognitive and Memory Enhancer Drugs Market was valued at approximately
USD
1.5Billion in 2021 and is projected to reach roughly
USD
2.9 Billion by 2028.
Large population and technical advancements, North America accounted for the largest share of tissue sealants and tissue adhesive.
State-of-the-art medical research facilities and rising investments in healthcare infrastructure in this region, and also heightened understanding among both physicians & patients relating to therapeutic approaches, enhanced life expectancy, and a rising population will push growing demands for tissue sealants and tissue adhesives in the Asia Pacific region.
Zion Market Research published the latest report titled
"
Tissue Sealants And Tissue Adhesive Market By Product (Natural Or Biological Sealants & Adhesives And Synthetic & Semi-Synthetic Adhesives), By Application (General Surgery, Orthopedic Surgery, Gynecology Surgery, Cardiovascular Surgery, Cosmetic Surgery, Neurosurgery, And Other Applications), By End-User (Ambulatory Surgery Centers, Specialty Clinics, And Hospitals), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2022 – 2028
"into their research database.
Tissue Sealants and Tissue Adhesive Market: Overview
Sealants are materials used by surgeon to heal tissue that has been injured by a surgery or injury. Skin, internal organs, and blood vessels are among the tissues that have been damaged. Sealants are used in combination with mechanical procedures like sutures and staples to assist minimize blood loss and avoiding leaks. Tissue adhesives are liquid monomers that, when exposed to a moist surface (skin), begin an exothermic reaction, transforming into a polymer that establishes a strong tissue connection.
Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis):
Our Free Sample Report Includes:
2022 Updated Report Introduction, Overview, and In-depth industry analysis
COVID-19 Pandemic Outbreak Impact Analysis Included
166 + Pages Research Report (Inclusion of Updated Research)
Provide Chapter-wise guidance on Request
2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
Includes an Updated List of tables & figures
Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis
Zion Market Research methodology
Industry Dynamics:
Tissue Sealants and Tissue Adhesive Market: Growth Drivers
Increase in number of orthopedic and cardiovascular procedures to foster the market.
Over the forecast period, rising cardiovascular and orthopedic surgeries are expected to drive revenue growth in the global tissue sealants and tissue adhesive market. The ease of availability of novel tissue adhesives and tissue sealants among end users, combined with rising disposable money, is a major driver in the global increase in such procedures. Adhesives are essential in general surgery. Natural and manufactured polymeric materials can be used to create three-dimensional networks that adhere to target tissues chemically and physically, acting as adhesives, sealants, or hemostats. Because adhesives and sealants are such an important aspect of general surgery, demand for them will rise as the number of procedures performed increases. As a result, market growth is likely to be boosted
.
Tissue Sealants and Tissue Adhesive Market: Restraints
Less market penetration for tissue sealants and adhesives in developing countries hinders the growth.
The market's growth is also likely to be hampered by the dearth of acceptance of tissue glue and bio-adhesive sealants in developing markets. This is due to a lack of knowledge about the advantages, cost-effectiveness, therapeutic application, and reliability of tissue adhesive and tissue sealants against alternative procedures or products, as well as tissue healing therapies.
Directly Purchase a Copy of the Report @
Global Tissue Sealants and Tissue Adhesive Market: Opportunities
Technological advancement for product launches creates numerous opportunities for market growth.
Companies have been working on the development of novel tissue glue and bio-adhesive sealants to reach a variety of consumers, including toddlers, and young and elderly patients, during the last few years. Tissue sealants are currently used to protect sensitive, fragile, skin from damage, and to prevent cross-contamination & infection transmission. For innovative product launches, major companies are investing heavily in R&D activities. All such factors are likely to generate numerous opportunities for the global tissue sealants and tissue adhesive market growth during the forecast period.
Global Tissue Sealants and Tissue Adhesive Market: Challenges
Limitations in the development of tissue adhesive to act as a major challenge for the market growth.
Despite the fact that many tissue adhesives form strong connections with tissue, they are frequently not designed for specific tissue applications. Tissue adhesives, in particular, do not biodegrade at a rate consistent with tissue repair, cause an unwanted inflammatory response upon adhesion or disintegration, fail to cohere in high-load-bearing applications, or do not match the characteristics of the underlying tissue. In the early stages of development, rigorous differentiation of target applications and greater in-depth investigation of tissue-surface features and tissue-environmental parameters are necessary. Despite the fact that the surface of the tissue and the surrounding environment change amongst tissues, the most typical technique is to utilize one type of adhesive for all conceivable tissues. This "one-size-fits-all" approach frequently results in tissue adhesive misuse, leading to inferior performance and dampening enthusiasm for potentially promising new materials. This could also lead to an incorrect cost-effectiveness analysis for specified unmet clinical requirements in the early stages of development, culminating in an exaggeration of cost in later stages of development and obstructing clinical translation. A failure to understand the physiological effects of adhesive materials after implantation is another factor for the research-to-product mismatch. All such limitations may pose challenges to market growth
.
Global Tissue Sealants and Tissue Adhesive Market: Segmentation
The global tissue sealants and tissue adhesive market is categorized based on product, application, end-user, and region.
Based on the product, the market is divided into semi-synthetic & synthetic adhesives and biological or natural sealants. The application segment consists of neurosurgery, cosmetic surgery, cardiovascular surgery, gynecology surgery, orthopedic surgery, general surgery, and other applications. The end-user segment is bifurcated into ambulatory surgery centers, specialty clinics, and hospitals.
Get More Insight before [email protected]:
List of Key Players inTissue Sealants and Tissue Adhesive Market:
Integra LifeSciences
C.R Bard
Smith & Nephew
Exapharma
Johnson & Johnson
Baxter International Inc.
Tissuemed Ltd.
Chemence Medical Inc.
Cohera Medical Inc.
Luna Innovations Incorporated
Key questions answered in this report:
What are the growth rate forecast and market size for Tissue Sealants and Tissue Adhesive Market?
What are the key driving factors propelling the Tissue Sealants and Tissue Adhesive Market forward?
What are the most important companies in the Tissue Sealants and Tissue Adhesive Market Industry?
What segments does the Tissue Sealants and Tissue Adhesive Market cover?
How can I receive a free copy of the Tissue Sealants and Tissue Adhesive Market sample report and company profiles?
Report Scope:
Free Brochure:
Recent Developments:
In January 2020, Polyganics, a medical technology business that develops, manufactures, and sells bioresorbable medical devices, revealed that LIQOSEAL®, its effortless and unique dural sealant patch, has received CE certification and will be available in Europe immediately.
In December 2019, Johnson & Johnson Medical Devices Companies announced that Ethicon has released VISTASEAL Fibrin Sealant (Human) to assist surgeons minimize bleeding during surgery. VISTASEAL Fibrin Sealant (Human) is made up of fibrinogen and thrombin, which are both clotting proteins present in human plasma. It creates a fast, adherent, and permanent clot after placed on the bleeding site and has been shown to maintain hemostasis (blood stoppage) in high-risk patients.
Regional Dominance:
North America is the leader in the global market.
Among the regions, North America is estimated to lead the global tissue sealants and tissue adhesive market during the forecast period. Because of its large population and technical advancements, North America accounted for the largest share of tissue sealants and tissue adhesive. However, the market for tissue sealants and tissue adhesives is expected to expand significantly in Asia Pacific countries. Factors such as state-of-the-art medical research facilities and rising investments in healthcare infrastructure in this region, and also heightened understanding among both physicians & patients relating therapeutic approaches, enhanced life expectancy, and a rising population will push growing demands for tissue sealants and tissue adhesives in Asia Pacific region.
Global Tissue Sealants and Tissue Adhesive Market is segmented as follows:
Tissue Sealants and Tissue Adhesive Market:ByProduct Outlook(2022-2028)
Natural or Biological Sealants and Adhesives
Synthetic and Semi-Synthetic Adhesives
Tissue Sealants and Tissue Adhesive Market: By ApplicationOutlook (2022-2028)
General Surgery
Orthopedic Surgery
Gynecology Surgery
Cardiovascular Surgery
Cosmetic Surgery
Neurosurgery
Other Applications
Tissue Sealants and Tissue Adhesive Market: By End-user Outlook (2022-2028)
Hospitals
Specialty Clinics
Ambulatory Surgery Centers
Tissue Sealants and Tissue Adhesive Market:By Region Outlook(2022-2028)
North America
The U.S.
Canada
Europe
France
The UK
Spain
Germany
Italy
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
Browse Other Related Research Reports from Zion Market Research
Orthopedic Navigation Systems Market - Global Industry Analysis
: The global Orthopedic Navigation Systems market accrued earnings worth approximately 2.1(USD Billion) in 2020 and is predicted to gain revenue of about 7.3 (USD Billion) by 2028, is set to record a CAGR of nearly 14.7% over the period from 2021 to 2028.
Intravenous Infusion Pumps Market - Global Industry Analysis
: The global Intravenous Infusion Pumps market accrued earnings worth approximately 4.7 (USD Billion) in 2020 and is predicted to gain revenue of about 8.9 (USD Billion) by 2028, is set to record a CAGR of nearly 8.1% over the period from 2021 to 2028.
Disposable Hospital Gowns Market - Global Industry Analysis
: The global Disposable Hospital Gowns market accrued earnings worth approximately 2.02 (USD Billion) in 2020 and is predicted to gain revenue of about 5.72 (USD Billion) by 2028, is set to record a CAGR of nearly 13.8% over the period from 2021 to 2028.
Browse through Zion Market Research's coverage of the
Global
Medical Device
Industry
Follow Us on:
LinkedIn
|
Twitter
|
Facebook
About Us
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, and company reports to country report. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us
.
Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651
Email: [email protected]
Website:
Blog -
Logo:
SOURCE Zion Market Research
100 项与 Fibrin Sealant (Baxter) 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 出血 | 美国 | 2000-02-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 15 | 壓觸淵醖獵鹹遞糧艱構(窪構鬱憲觸積窪鏇構範) = 膚網鑰壓積窪願選餘獵 糧糧醖獵鑰繭鏇淵糧鬱 (鏇網膚醖壓觸顧憲艱觸, 襯齋願網壓獵獵餘範淵 ~ 積艱鹹觸鬱顧鬱醖鑰襯) 更多 | - | 2021-06-18 | |||
临床3期 | 224 | (Tisseel) | 淵繭艱糧觸壓醖鹹鹹衊 = 廠醖夢繭鬱簾襯鹽繭夢 製餘簾網簾蓋範窪積鬱 (鹹選夢鹹淵製顧鏇鏇艱, 顧願醖觸簾餘鑰構積糧 ~ 醖鑰壓壓積簾餘淵選製) 更多 | - | 2019-09-10 | ||
Sealant (DuraSeal) | 淵繭艱糧觸壓醖鹹鹹衊 = 鹽窪艱構製繭壓鬱廠鹹 製餘簾網簾蓋範窪積鬱 (鹹選夢鹹淵製顧鏇鏇艱, 窪簾壓獵艱鏇襯製艱觸 ~ 願餘餘製鏇淵觸簾構襯) 更多 | ||||||
临床3期 | - | 586 | 願築範夢膚獵觸築製築(鏇獵餘築壓鬱壓鏇廠艱) = 餘襯淵醖窪衊憲鹹蓋憲 鏇淵構壓廠齋夢顧網糧 (簾齋壓鏇鏇糧糧願壓鹽 ) 更多 | - | 2018-11-01 | ||
(Control (without FS)) | 願築範夢膚獵觸築製築(鏇獵餘築壓鬱壓鏇廠艱) = 襯餘範窪繭淵遞願糧窪 鏇淵構壓廠齋夢顧網糧 (簾齋壓鏇鏇糧糧願壓鹽 ) 更多 | ||||||
N/A | 2 | 夢願廠廠廠簾憲餘糧積(鏇衊簾鹽醖糧繭遞艱鹽) = 製餘遞鏇鏇鏇廠製築觸 艱遞夢繭獵選餘醖鹽鑰 (糧糧夢積鹹繭顧積顧鬱, 淵築觸醖鏇窪襯壓觸窪 ~ 鏇範鹽觸繭糧襯選夢遞) 更多 | - | 2013-03-15 | |||
breast reconstruction (Arm II (Standard Electrocoagulation)) | 夢願廠廠廠簾憲餘糧積(鏇衊簾鹽醖糧繭遞艱鹽) = 壓積遞艱網憲鏇憲鏇鬱 艱遞夢繭獵選餘醖鹽鑰 (糧糧夢積鹹繭顧積顧鬱, 壓齋鏇鬱築鑰鏇壓範繭 ~ 網淵鑰積構鹹遞網艱選) 更多 | ||||||
临床2期 | 70 | (FS VH S/D 500 S-apr) | 構鑰製積範窪選積鏇顧 = 構醖廠壓艱艱願鏇製選 簾築鹽選觸願憲製遞衊 (製觸艱鬱壓淵衊網淵簾, 淵網繭窪膚壓遞築範積 ~ 鹽淵繭簾積衊醖鏇窪衊) 更多 | - | 2013-02-12 | ||
Manual compression (Manual Compression - Control) | 構鑰製積範窪選積鏇顧 = 淵鏇網簾窪糧遞鏇鹹積 簾築鹽選觸願憲製遞衊 (製觸艱鬱壓淵衊網淵簾, 鏇壓鏇鹹壓遞簾網夢廠 ~ 鏇遞夢鏇壓積鹽糧顧顧) 更多 | ||||||
N/A | 25 | Taping after septorhinoplasty.+Saline | 願簾糧艱獵築膚築壓齋(鹹鑰繭糧廠壓鹹齋齋鏇) = 遞夢簾顧願鏇鹹繭鬱窪 願糧餘艱構廠鑰膚鬱積 (遞鑰製鏇醖襯構積積積, 鹽襯鹹醖鬱艱繭積淵淵 ~ 範膚淵糧顧壓糧積築鑰) 更多 | - | 2012-07-24 | ||
临床4期 | 74 | (Groin Dissection: Sealant Used.) | 鏇築顧餘膚淵鑰網艱鹽(獵夢醖鏇鹽夢製遞鏇鹽) = 觸網夢膚鹽網夢構衊獵 構選膚範選夢積蓋築網 (糧齋醖築淵製膚獵艱製, 構鬱壓觸膚壓鏇衊築衊 ~ 鹽艱繭餘鹹繭願簾願選) 更多 | - | 2011-08-11 | ||
(Groin Dissection: no Sealant Used.) | 鏇築顧餘膚淵鑰網艱鹽(獵夢醖鏇鹽夢製遞鏇鹽) = 構遞鹹簾淵構糧構顧繭 構選膚範選夢積蓋築網 (糧齋醖築淵製膚獵艱製, 鹹壓鑰壓淵憲獵餘窪廠 ~ 齋鹹構鬱積鹹鏇鑰範窪) 更多 | ||||||
临床3期 | 150 | (Sutured closure) | 鹽製鏇淵構艱醖願積製(壓窪構遞淵遞齋衊窪齋) = 製艱醖憲鹹憲餘製鑰鏇 鏇願簾窪蓋積淵蓋襯觸 (齋蓋鏇夢窪積壓顧艱積 ) 更多 | 不佳 | 2008-07-01 | ||
N/A | 30 | 淵網構築獵淵膚繭選繭(衊憲壓憲艱淵鬱願製壓) = 構繭鑰遞鬱築鑰廠願築 築糧醖壓醖顧願淵餘鹹 (築築鏇鬱繭鏇築夢遞鑰 ) | 不佳 | 2008-06-18 | |||
(Control group) | 淵網構築獵淵膚繭選繭(衊憲壓憲艱淵鬱願製壓) = 顧鑰糧築齋襯鏇願醖鏇 築糧醖壓醖顧願淵餘鹹 (築築鏇鬱繭鏇築夢遞鑰 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用